Science Corp raises $400M Series D to scale PRIMA retinal implant in Europe and US
emmanuelvivier · x · 2026-11-18
Science Corporation announced a $400 million Series D, bringing total capital since its 2021 founding to over $900 million. The funding accelerates the European rollout of its PRIMA retinal implant, prepares a US launch, expands R&D and manufacturing, and funds its biohybrid neural-interface program.
Investors include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. PRIMA received CE mark under the EU MDR and launched commercially across 30 European countries in July 2026; its 36-month trial showed a mean 29-letter vision improvement with no new safety signal after month 12.
More from Venture
- Indie dev shares inbound DM: buyer asking to acquire his tool Steercamp — pramodk73 · 2026-11-22
- Anthropic's record ~$81B IPO, GPT-6.2 pricing, Qwen4-Max and Copilot Autopilot: week in review — ksraj1001 · 2026-11-22
- Users want frontier AI at bargain prices while complaining labs aren't profitable — VraserX · 2026-11-22
- MCP server checks if a pay-per-call x402 API is worth paying, from 24,766 real paid calls — biryaniAssasin · 2026-11-22
- Plausible took 324 days to hit $400 MRR, then a HN post fueled $500K ARR — sven_ai · 2026-11-22
- Token economics model projects $1.14T global API spend by 2030, but only 1% of users pay beyond coding — AccBalanced · 2026-11-22